Caris Life Sciences, Inc.
CAI
$38.39
-$0.09-0.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -8.47% | 7.61% | |||
| Total Depreciation and Amortization | -44.80% | -60.21% | |||
| Total Amortization of Deferred Charges | 347.75% | 22.33% | |||
| Total Other Non-Cash Items | 1,212.36% | 157.65% | |||
| Change in Net Operating Assets | 65.05% | 1,225.08% | |||
| Cash from Operations | 111.58% | 57.61% | |||
| Capital Expenditure | 46.45% | -54.72% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | 46.45% | -104.51% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | 26.67% | 72.50% | |||
| Issuance of Common Stock | 134,670.74% | 582.86% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 980.08% | -- | |||
| Cash from Financing | 528,318.60% | -99.36% | |||
| Foreign Exchange rate Adjustments | 675.00% | 300.00% | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 1,147.37% | -117.62% | |||